July 28, 2010
Bioamber, a joint venture between DNP Green Technology and ARD, and DuPont Applied BioSciences, have announced a licensing agreement in the field of biobased derivatives of succinic acid. Under the terms of the agreement, Bioamber has licensed certain DuPont technology and DuPont has a right of first refusal to secure off-take from future commercial plants.
Bioamber, which recently commissioned the world's first biobased succinic acid plant, is actively developing technologies to transform biobased succinic acid into value-added derivative products. "DuPont's technology will accelerate our development program and shorten our time to market," stated Jean-Francois Huc, President of DNP Green. "Our agreement with DuPont Applied BioSciences will help ensure that we are first to market, and it could reduce the commercial risk associated with building large plants," he added.
DuPont Applied BioSciences is executing a rapid commercialization strategy for a diverse portfolio of high-performance, renewable products that address the needs of global markets in need of innovation. "We are committed to delivering new biobased technologies to global markets, through our own routes as well as through technology licensing" said Michael Saltzberg, global business director - DuPont BioSpecialties. "We are pleased Bioamber has value for this specific technology."
Sections of this page are funded by the Community Investment Support Program, International Trade Canada
and the Ontario Ministry of Economic Development and Trade. Thank You!
